Table 2 Prevalence of interleukin-1 receptor antagonist gene polymorphisms (IL-1RA) and serostatus of CMV and their combination in patients with and without cardiovascular events during follow-up
Patients with Cardiovascular Event (n = 60) | Patients without Cardiovascular Event (n = 240) | p-value | |
|---|---|---|---|
IL-1 RA | |||
- othera | 55 (91.7%) | 215 (89.6%) | |
- Il-1RN*2 | 5 (8.3%) | 25 (10.4%) | 0.6 |
CMV-serostatusb | |||
- negative | 29 (49.2%) | 110 (46.8%) | |
- positive | 30 (50.9%) | 125 (53.2%) | 0.7 |
IL-1 RA and CMV serostatus | |||
- IL-othera and CMV-negative | 27 (45.8%) | 96 (40.9%) | |
- IL-othera and CMV-positive | 27 (45.8%) | 114 (48.5%) | |
- Il-1RN*2 and CMV-negative | 2 (3.4%) | 14 (6.0%) | |
- Il-1RN*2 and CMV-positive | 3 (5.1%) | 11 (4.7%) | 0.8c |